Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALG-000184 in chronic hepatitis B
NCT04536337Phase 1Completed
- Sponsor
- Aligos Therapeutics
- Start
- Oct 2020
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, randomised, double-blind trial of pevifoscorvir in Chronic Hepatitis B (CHB) (5 arms), sponsored by Aligos Therapeutics. Primary endpoint: Treatment-Emergent Adverse Events at 756 days. Started Oct 2020; status: completed.
02
Drugs
pevifoscorvir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04536337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04536337.